Shree Ganesh Remedies Limited

Equities

SGRL6

INE414Y01015

Biotechnology & Medical Research

Market Closed - Bombay S.E. 06:00:48 2024-05-08 am EDT 5-day change 1st Jan Change
609.8 INR +0.02% Intraday chart for Shree Ganesh Remedies Limited -2.23% -10.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shree Ganesh Remedies Begins Trial Run of Plant in Gujarat, India MT
Shree Ganesh Remedies Limited Announces Company Secretary and Compliance Officer Changes CI
Shree Ganesh Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Shree Ganesh Remedies Limited Announces the Reconstitution of Committees and Resignation of Directors CI
Shree Ganesh Remedies Limited Announces Director Appointments CI
Shree Ganesh Remedies Limited Proposes Final Dividend for Financial Year 2022-23, Payable on 25 September, 2023 CI
Shree Ganesh Remedies Forms New Wholly-Owned Subsidiary in US MT
Shree Ganesh Remedies Limited Announces Intimation for Incorporation of Wholly Owned Subsidiary Company Named Sgrl Usa Inc in United States CI
Shree Ganesh Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Shree Ganesh Remedies Gets License to Manufatcure Drugs, Other Products in Gujarat, India MT
Shree Ganesh Remedies Limited Receives Receipt of FDA License CI
Shree Ganesh Remedies Limited Recommends Final Dividend for the Year Ended March 31, 2023 CI
Shree Ganesh Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Shree Ganesh Remedies Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Shree Ganesh Remedies CFO Resigns MT
Shree Ganesh Remedies Books Higher Net Profit in Fiscal Q3 MT
Shree Ganesh Remedies Appoints CFO MT
Shree Ganesh Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Shree Ganesh Remedies Limited Announces Appointment of Parth Kothia as Chief Financial Officer CI
Shree Ganesh Remedies' CFO Resigns MT
Shree Ganesh Remedies Limited Announces Resignation of Suresh Panchal as Chief Financial Officer CI
Shree Ganesh Remedies Signs Pact to Acquire Land Asset in Gujarat, India MT
Shree Ganesh Remedies Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Shree Ganesh Remedies' Net Profit Jumps in Fiscal Q1 MT
Shree Ganesh Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Chart Shree Ganesh Remedies Limited
More charts
Shree Ganesh Remedies Limited is an India-based company, which is engaged in the business of bulk drug intermediates. The Company is a supplier of pharmaceutical intermediates and specialty chemicals with chlorination, Grignard reaction, hydrogenation, and high-vacuum distillation. The Company's products include intermediates by active pharmaceutical ingredient (API), and fine and specialty chemicals. It offers services, including customized chemistry and manufacturing, assets and infrastructure and key technologies and expertise. It offers its solutions to the markets, such as life sciences: human health and veterinary, flavor and fragrance, polymer industries, electronics, and agro chemicals. The Company has a portfolio of approximately 39 drug intermediates, and 18 specialty chemical products. It also delivers a service of contract manufacturing for chemical reactions like amination, amidation, alkylation, bromination, catalytic hydrogenation and chlorination.
More about the company
  1. Stock Market
  2. Equities
  3. SGRL6 Stock
  4. News Shree Ganesh Remedies Limited
  5. Shree Ganesh Remedies Forms New Wholly-Owned Subsidiary in US
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW